Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Maternal Methyl-Group Donor Intake and Neonatal Birth Size in Singleton IVF Pregnancies.

Nutrients·2026

Same author

Delayed diagnostic imaging but stable treatment initiation for kidney cancer during the COVID-19 pandemic: a Hungarian cohort study.

Pathology oncology research : POR·2026

Same author

A Unique Patient Stratification Method Combined with a Machine Learning Approach Identifies Novel Genetic Susceptibility and Protective Factors for Severe COVID-19 in a Hungarian Population.

International journal of molecular sciences·2026

Same author

Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study.

The journal of pathology. Clinical research·2026

Same author

Somatic Mutations in Nuclear and Mitochondrial Genes of Mitochondrial Proteins in Primary and Recurrent Glioblastoma.

International journal of molecular sciences·2026

Same author

Emergence of OXA-48-like Carbapenemase-Producing <i>Escherichia coli</i> in Baranya County, Hungary.

Antibiotics (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: Jan 9, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Comprehensive Genomic Profiling of Small-Cell Lung Cancer Reveals Frequent Potentially Targetable Alterations.

Dániel Schmalz¹, Zoltán Krabóth², Veronika Czoma²

¹Center of Omics, János Szentágothai Research Center, University of Pécs, Ifjúság Street 20, 7624 Pécs, Hungary.

International Journal of Molecular Sciences

|December 11, 2025

Summary

Genomic profiling of small-cell lung cancer (SCLC) reveals significant molecular diversity. Novel therapeutic targets, including TYRO3 and SDHA, were identified, offering new avenues for precision oncology.

Keywords:

NGS SCLC TYRO3 comprehensive genomic profiling copy number changes

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Experiment Videos

Last Updated: Jan 9, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Area of Science:

Oncology
Genomics
Molecular Biology

Background:

Small-cell lung cancer (SCLC) is an aggressive malignancy with limited precision oncology options.
Despite uniform morphology, SCLC displays significant molecular heterogeneity and actionable genomic alterations.
Tissue limitations and rapid progression necessitate efficient molecular profiling.

Purpose of the Study:

To comprehensively characterize the genomic landscape of SCLC.
To identify novel, potentially targetable genomic alterations in SCLC.
To explore the utility of next-generation sequencing for SCLC precision therapy.

Main Methods:

Genomic profiling of 55 primary and metastatic SCLC samples.
Utilized a 324-gene hybrid-capture next-generation sequencing panel.
Analyzed recurrent alterations, copy-number variations, and novel amplifications.

Main Results:

Confirmed frequent biallelic TP53 and RB1 inactivation.
Identified recurrent alterations in PI3K/Akt/mTOR (62%), chromatin regulators (42%), and NOTCH (15%).
Discovered novel amplifications in TYRO3 (33%) and SDHA (13%), with PTEN mutations enriched in brain metastases.

Conclusions:

SCLC exhibits substantial genomic diversity, challenging traditional classification.
TYRO3 and SDHA represent emerging therapeutic vulnerabilities in SCLC.
Broad genomic profiling is crucial for uncovering SCLC molecular targets and advancing precision therapy.